Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
SusmedTSE:4263 -2.51%60 EV-to-EBIT is -16.53 as of Aug. 18, 2026. GuruFocus rates TSE:4263 with a GF Score™ of 60/100 and a GF Value™ of 円919.23 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 473 Healthcare Providers & Services companies, Susmed ranks worse than 211416.28% on this metric.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Susmed's Enterprise Value is 円5,457.7 Mil.
Susmed's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 was 円-330.2 Mil. Therefore, Susmed's EV-to-EBIT for today is -16.53.
The historical rank and industry rank for Susmed's EV-to-EBIT or its related term are showing as below:
TSE:4263'
s EV-to-EBIT Range Over the Past 10 Years
Min: -640.4 Med: -45.66 Max: 10988.12
Current: -16.53
During the past 7 years, the highest EV-to-EBIT of Susmed was 10988.12. The lowest was -640.40. And the median was -45.66.
TSE:4263's EV-to-EBIT is ranked worse than 100% of 473
companies
in the Healthcare Providers & Services industry
Industry Median: 15.81
vs TSE:4263: -16.53
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Susmed's Enterprise Value for the quarter that ended in Mar. 2026 was 円12,280.0 Mil.
Susmed's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was 円-330.2 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Susmed EV-to-EBIT Related Terms
Susmed EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Susmed's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSE:4263 vs VEEV, BTSG, HQY: EV-to-EBIT Comparison
For the Health Information Services subindustry, Susmed's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Susmed EV-to-EBIT vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Susmed's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Susmed's EV-to-EBIT falls into.
Susmed's current Enterprise Value is 円5,457.7 Mil.
Susmed's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was 円-330.2 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Susmed (TSE:4263) has a EV-to-EBIT of -16.53 as of Aug. 18, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Susmed and its competitors. According to the industry distribution chart, Susmed ranks #999999 out of 473 companies in the Healthcare Providers & Services industry.
Is Susmed's EV-to-EBIT too high?
Susmed's current EV-to-EBIT is -16.53. Based on the distribution chart, Susmed ranks #999999 out of 473 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, Susmed has a GF Score™ of 60/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Susmed's EV-to-EBIT compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, Susmed ranks #999999 out of 473 companies for EV-to-EBIT. This places Susmed in the lower half of its industry. The industry median EV-to-EBIT is 15.81. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Healthcare Providers & Services company?
The median EV-to-EBIT among Healthcare Providers & Services companies is 15.81, based on 473 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Susmed and its competitors. For the Healthcare Providers & Services industry, the median EV-to-EBIT is 15.81 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Susmed's current EV-to-EBIT is -16.53. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Susmed stock overvalued right now?
Based on GuruFocus' analysis, Susmed (TSE:4263) is currently considered Possible Value Trap. The stock's GF Value™ is 円919.23, compared to a current price of 円543.00 — trading 40.9% below its estimated fair value. The current EV-to-EBIT is -16.53. Susmed's overall GF Score™ is 60/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Susmed (TSE:4263), the current EV-to-EBIT is -16.53 as of Aug. 18, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Susmed (TSE:4263) Overvalued in 2026?
Based on GuruFocus' analysis, Susmed stock appears to be undervalued.
The current stock price of 円543.00 is trading 40.9% below its estimated GF Value™ of 円919.23.
GuruFocus considers Susmed to be Possible Value Trap.
Key valuation signals for TSE:4263:
EV-to-EBIT: -16.53
GF Value™: 円919.23 vs. price of 円543.00 (40.9% below fair value)
No single metric tells the full story. See the TSE:4263 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Susmed Inc is engaged in the development of therapeutic smartphone apps and digital solutions to streamline clinical trials. It is currently developing therapeutic apps for patients with insomnia, breast cancer, kidney disease, and other conditions. In addition, it has developed Susumed System, which uses a proprietary blockchain technology to ensure the reliability of clinical trial data, and can reduce the manpower and costs allocated to clinical trials. The company's reportable segments are: the DTx Product Business, which derives maximum revenue, and consists of the development of therapeutic apps; and the DTx Platform Business, which provides general-purpose clinical trial systems and machine learning automated analysis systems.
60GF Score
Get the complete analysis for TSE:4263
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:4263 has been successfully added to your 
